Research Associate, Vienna
Parallel Bio, Vienna
About the job
The mission
Drug discovery has a translation problem: more than 95% of drugs that succeed in animal models fail in humans. We're building the alternative: human-first drug discovery, powered by organoids and AI, running on real human biology from the very first experiment.
Our platform is 87% concordant with clinical patient data - a vast improvement over the 3% translational success rate of animals. We’ve demonstrated the ability to model immunotoxicology, immunogen stimulation, and two autoimmune diseases with more on the way. Numerous pharma partners including 3 Fortune 500 companies are already using the platform. We've raised ~$30M from AIX Ventures, Marc Benioff, Jeff Dean, and Y Combinator. With the FDA Modernization Act 3.0 and the FDA's March 2026 validation framework, the regulatory tailwinds only continue to get stronger.
The opportunity ahead of the company is generational: build the first scaled engine for generating real human biological data, and use it to fundamentally change how medicines are discovered.
The role
Derivation, quality control and biobanking
- Derive iPSC lines from donor blood, from cell isolation through colony picking, clonal expansion and cryopreservation.